Malignant ascites protect against TRAIL‐induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells
Open Access
- 23 July 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 121 (6) , 1227-1237
- https://doi.org/10.1002/ijc.22840
Abstract
Ascites are commonly found in ovarian cancer patients with advanced disease and are rich in cellular components and growth-promoting factors. The purpose of this study was to assess the effect of malignant ascites on TRAIL-induced apoptosis. We demonstrate that malignant ascites obtained from women with advanced ovarian cancer protect tumor cells from TRAIL- and FasL-induced apoptosis but not against cisplatin-induced apoptosis. This antiapoptotic effect was consistently found among different malignant ascites while nonmalignant peritoneal fluids or conditioned medium from TRAIL-resistant cells failed to protect tumor cells against TRAIL killing. Malignant ascites strongly inhibits TRAIL-induced caspase-3 activation and PARP cleavage. Furthermore, ascites activate PI3K and its downstream target Akt and increases c-FLIPS protein levels without affecting ERK phosphorylation status. The antiapoptotic effect of malignant ascites is abrogated by the inhibition of PI3K with LY294002, by a specific inhibitor of Akt and by Akt siRNA. We further show that the pro-survival effect of ascites can be suppressed by down-regulation of c-FLIPS. Our data indicate that malignant effusions protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway. These findings demonstrate that the tumor microenvironment may contribute to the resistance of ovarian cancer cells to death receptor-induced apoptosis.Keywords
This publication has 42 references indexed in Scilit:
- Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3Molecular Cancer Therapeutics, 2006
- Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cellsGynecologic Oncology, 2004
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003
- Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumorZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugsEuropean Journal Of Cancer, 2002
- Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer CellsGynecologic Oncology, 2001
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- An Induced Proximity Model for Caspase-8 ActivationJournal of Biological Chemistry, 1998
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996